Official Title: “An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients”

The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: Pregabalin
• Drug: Venlafaxine XR

Primary Measures

• Evaluation of the efficacy of pregabalin and Venlafaxine XR in the treatment of generalized anxiety disorder.

Inclusion Criteria:

• Male and female outpatients with diagnosis of generalized anxiety disorder.

Exclusion Criteria:

• Any serious or uncontrolled medical condition.
• Current diagnosis of depression, dysthymia, obsessive-compulsive disorder.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Pfizer

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on February 08, 2010

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00151450

Study ID Number: A0081012

ClinicalTrials.gov Identifier: NCT00151450

Health Authority: Belgium: Directorate general for the protection of Public health: Medicines

To obtain contact information for a study center near you, click here.

Link to ClinicalStudyResults.org Posting